一种口服聚醇宿主-客人纳米粒子,用于针对性治疗炎症性肠道疾病
Chong Zhang1, Fen Zeng1, Zhengyang Fan1
1Liaoning Key Laboratory of Molecular Recognition and Imaging, School of Bioengineering, Dalian University of Technology, Dalian 116023, PR China.
Acta biomaterialia
|August 19, 2023
概括
一种新的口服多纳米粒子 (PDT) 通过向炎症组织并减少副作用,有效治疗炎症性肠病 (IBD). 这种安全,快速的纳米粒子输送系统显示出IBD治疗的前景.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 胃肠病学 胃肠病学
背景情况:
- 炎症性肠病 (IBD) 是一个重大的全球健康挑战,目前的治疗方法往往缺乏有效性并引起副作用.
- 对于管理IBD的新,安全和有效的治疗策略有着至关重要的需求.
- 开发有针对性的药物输送系统可以改善治疗结果,并最大限度地降低全身毒性.
研究的目的:
- 开发一种新的口服多纳米粒子 (PDT),用于针对性地输送甲酸 (DSP) 用于IBD治疗.
- 调查开发的PDT的物理化学特性,准能力和治疗疗效.
- 建立一个简单和安全的宿主-客组装方法,用于纳米医学开发.
主要方法:
- 一种口服的多纳米颗粒 (PDT) 通过DSP载荷的多β-环氧和酸之间的宿主-客人相互作用来合成.
- 在体外和体外评估了PDT的电荷,稳定性和药物释放动力学.
- 使用大肠炎小鼠模型评估了对炎症结肠粘膜的向能力和治疗疗效.
主要成果:
- PDT的单步组装速度快 (<10秒),可重复,并且没有有害化学物质.
- 负电荷的PDT对正电荷的炎症结肠组织表现出特定的静电吸引力,使得药物可以被向地输送.
- 与自由的DSP相比,PDT在结肠炎小鼠模型中表现出显著的反应性氧物种 (ROS) 清除活性,持续的药物释放,以及增强的治疗疗效.
结论:
- 开发的口服聚纳米颗粒 (PDT) 是炎症性肠病 (IBD) 的有前途的治疗剂,因为其有针对性的输送,ROS-scavenging特性和持续的药物释放.
- 简单的宿主-客户组装策略为开发针对各种疾病的定制纳米药物提供了一个多功能平台.
- PDT代表了IBD治疗的安全,简单和有效的策略,可能减少全身暴露和副作用.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
355
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
355
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
495
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
495


